BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months

- Phase 3 open-label, single-arm study conducted in Japan by BridgeBio licensing partner Alexion, AstraZeneca Rare Disease showed consistency with global ATTRibute-CM Phase III trial

- No mortality was reported over the 30 month acoramidis treatment period

- Acoramidis was well-tolerated, with no safety signals of potential clinical concern identified

- These results support local regulatory submission in Japan

- The findings from this study build upon positive results from BridgeBio’s global ATTRibute-CM Phase 3 trial, where the primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p